Sanofi India Gets ₹36.39 Crore GST SCN Plus Equal Proposed Penalty Over Classification

Finin2min 2-minute summary

Sanofi India has disclosed receipt of a GST show-cause notice under Section 74 of the CGST Act for FY 2020-21. The notice alleges that certain products were classified at a concessional 5% GST rate instead of 12%.

The tax proposed in the notice is ₹36,38,70,979. The notice also proposes a penalty of ₹36,38,70,979. Together, the two proposed components are about ₹72.77 crore, but that combined figure must not be described as a final liability or final demand.

SCN is not a final order

This distinction is critical. A show-cause notice sets out the tax authority's allegation and proposed consequence and gives the taxpayer an opportunity to respond. Liability is not finally determined merely because an SCN has been issued.

Sanofi says it is examining the notice with consultants and tax advisers and will submit a reply within the prescribed period. It also says it does not envisage an adverse impact on its financials, operations or other activities arising from the SCN. That is management's current assessment, not a regulator finding.

The classification dispute

GST classification determines the applicable tax rate. A difference between 5% and 12% can become material when applied retrospectively across a sizeable turnover base. The dispute can involve tariff headings, product composition, end use, exemptions, interpretive circulars and judicial precedents.

For pharmaceutical companies, classification can be especially technical because products may contain multiple ingredients, have therapeutic or nutritional characteristics, or sit near boundaries between tariff entries.

Section 74 lens

Sanofi's filing says the notice was issued under Section 74 of the CGST Act. The section reference should not be converted into a factual finding that misconduct occurred; the allegations still require adjudication.

Finance and legal teams should separate:

• amount proposed in the SCN;
• amount accepted, if any;
• provision or contingent-liability accounting;
• final adjudication;
• appellate remedies and stays.

Accounting lens

Receipt of an SCN does not automatically determine the accounting entry. Management must assess probability of outflow and the relevant accounting standard based on facts, legal advice and past precedent.

A market headline that simply adds proposed tax and penalty and calls the result liability would therefore be misleading.

Investor lens

The amount should be compared with Sanofi India's earnings, cash balance and materiality thresholds, but the more important question is legal strength. A smaller dispute with weak facts can be more economically significant than a larger disputed amount with strong precedent.

Investors should also watch whether the issue is product-specific or could affect classification in later tax periods.

Compliance lessons

Businesses should maintain contemporaneous classification memos, product specifications, tariff analysis, advance-ruling or judicial references where relevant, and evidence supporting the selected rate. Rate positions should be revisited when product composition, law or interpretations change.

What to watch next

• Sanofi's formal reply to the SCN.
• The exact product categories under dispute.
• Any adjudication order.
• Accounting disclosure in future results.
• Appeal or stay proceedings if an adverse order is passed.
• Whether later periods contain the same classification issue.

Finin2min view

The right headline is ₹36.39 crore proposed tax plus equal proposed penalty in an SCN, not ₹72.77 crore GST liability. Preserving procedural status is essential in tax reporting because a proposal, an adjudicated demand and a finally payable amount are legally and economically different.

For information and education only. This is not tax, legal, accounting or investment advice.